Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Date:2/24/2010

AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

    Highlights
    - Glybera(R) Marketing Authorisation Application submitted to
      European Medicines Agency (EMA, formerly known as EMEA);
    - EMA commenced formal review of Glybera(R) dossier on January
      20, 2010;
    - EMA grants orphan drug designation for AMT's Acute
      Intermittent Porphyria ("AIP") program;
    - EMA grants orphan drug designation for AMT's Duchenne
      Muscular Dystrophy ("DMD") program;
    - SenterNovem awards EUR 4 million investment credit for the
      development of AMT's DMD program;
    - Raised EUR 5 million convertible loan notes, which convert
      into ordinary shares at EUR 3.91 per share;
    - New management team.

Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our strategy, focused on our lead product Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD), together with the ongoing development of four earlier stage progams targeting:
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. Amsterdam Molecular Therapeutics Part of Next Biotech Index
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Stage Product Targeting Life-threatening Hereditary ... to Host Conference Call at 10:30 A.M. Eastern Today to Discuss ... ... Incorporated,(Nasdaq: VPHM ) and Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP),today ...
... July 15 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin ... firm specializing in the manufacture,research, development, marketing ... appointment of American Stock Transfer & Trust ... registrar, effective August 15, 2008.,AST, headquartered in ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... results will be released on,Thursday, July 31, 2008. The ... 10:00 a.m. Eastern Time, July 31, 2008, to discuss ... by Steven G.,Anderson, president and CEO of CryoLife, Inc., ...
Cached Biology Technology:ViroPharma To Acquire Lev Pharmaceuticals 2ViroPharma To Acquire Lev Pharmaceuticals 3ViroPharma To Acquire Lev Pharmaceuticals 4ViroPharma To Acquire Lev Pharmaceuticals 5ViroPharma To Acquire Lev Pharmaceuticals 6ViroPharma To Acquire Lev Pharmaceuticals 7ViroPharma To Acquire Lev Pharmaceuticals 8ViroPharma To Acquire Lev Pharmaceuticals 9China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008 2CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:4/22/2014)... Consortium Ltd.,s nanotechnology expert will present a poster ... at the 7th International Nanotoxicology Congress to ... , Dr. Monita Sharma will outline a strategy consistent ... of Sciences, " Toxicity Testing in the 21st Century: ... of non-animal methods involving human cells and cell lines ...
(Date:4/22/2014)... University of Kentucky has discovered new methods to build ... The research, led by Peixuan Guo, professor and ... College of Pharmacy and Markey Cancer Center, is reported ... Polymer Material To Build Robust Structures with Defined Shape ... L. Jasinski. , The article, which will appear in ...
(Date:4/22/2014)... Many research projects study the effects of temperature and ... species. However, an important component of climate research, the ... UFZ in collaboration with their colleagues from the Universities ... data from the U.S. NASA space agency in such ... the influence of UV-B radiation on organisms. , The ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2UV-radiation data to help ecological research 2
... guidelines being used by foresters and the timber industry ... trees., Maps developed by Laura Gray, a post-doctoral fellow ... climatically suitable habitat for tree species based on climate ... work, published recently in the journal Climatic Change ...
... HZB physicist Dr. Philippe Wernet, chemist Prof. Dr. Athina Zouni ... SLAC National Accelerator Laboratory and Dr. Junko Yano of the ... project. In spite of the fact that all ... of it. Because as part of photosynthesis, green plants, algae, ...
... become stiff after middle age, a new study has revealed., ... compensate for the effects of obesity. But after middle age, ... body fat rises potentially increasing the risk of dying ... of body fat may be related to the total number ...
Cached Biology News:Snap shots of 1 of life's central processes 2Body fat hardens arteries after middle age 2
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: